APA (7th ed.) Citation

JS, K., HNI, A., DK, K., TH, Y., JH, C., Z, L., . . . M, C. (2026). Pharmacologic activation of PHD2 sensitizes non-small cell lung cancer cells to osimertinib. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 200, 119443. https://doi.org/10.1016/j.biopha.2026.119443

Chicago Style (17th ed.) Citation

JS, Kim, et al. "Pharmacologic Activation of PHD2 Sensitizes Non-small Cell Lung Cancer Cells to Osimertinib." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 200 (2026): 119443. https://doi.org/10.1016/j.biopha.2026.119443.

MLA (9th ed.) Citation

JS, Kim, et al. "Pharmacologic Activation of PHD2 Sensitizes Non-small Cell Lung Cancer Cells to Osimertinib." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 200, 2026, p. 119443, https://doi.org/10.1016/j.biopha.2026.119443.